Accenture have just blogged about the current strategic priorities of the 20 largest pharmaceutical companies (on their life sciences blog). What is interesting is how many of these are operational issues, specifically tagged in our blog. I’ll just focus on these..
Of more priority in the operations arena is delivering new product launches, cost reduction, and acquisition of other companies with innovative products. Of less priority than before is new business models, organisational culture, product life cycle management and corporate social responsibility.
This neatly illustrates how operations strategy has to fit with the overall strategy of the organisation, and mesh with the firm’s financial, human resource and marketing strategies. This sector in particular, apparently driven by the tax regime in the USA, is in the midst of much merger and acquisition activity. This inevitably affects operational priorities.